The question is what internal assumptions are baked into FMI's existing guidance. If they anticipated getting Medicare reimbursement for NSCLC tests in early 2017, then this news wouldn't in itself cause an upward revision in guidance.
p.s. I don't follow FMI as closely as I did two years ago.